BridgeBio Pharma, Inc. Quarterly Cost of Revenue in USD from Q2 2022 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate cost of goods produced and sold and services rendered during the reporting period.
Summary
BridgeBio Pharma, Inc. quarterly/annual Cost of Revenue history and growth rate from Q2 2022 to Q3 2024.
  • BridgeBio Pharma, Inc. Cost of Revenue for the quarter ending September 30, 2024 was $598K, unchanged year-over-year.
  • BridgeBio Pharma, Inc. Cost of Revenue for the twelve months ending September 30, 2024 was $2.39M.
  • BridgeBio Pharma, Inc. annual Cost of Revenue for 2023 was $2.45M, a 28.8% decline from 2022.
  • BridgeBio Pharma, Inc. annual Cost of Revenue for 2022 was $3.43M, a 10.3% increase from 2021.
Cost of Revenue, Trailing 12 Months (USD)
Cost of Revenue, Quarterly (USD)
Cost of Revenue, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $2.39M $598K $0 0% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 $2.39M $598K -$1K -0.17% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 $2.39M $598K -$53K -8.14% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-02
Q4 2023 $2.45M $598K Oct 1, 2023 Dec 31, 2023 10-K 2024-02-22
Q3 2023 $598K -$141K -19.1% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 $599K -$101K -14.4% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 $651K Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q3 2022 $739K Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $700K Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.